Traitanon O et al. - Enteric-coated mycophenolate sodium (EC-MPS) provides salutary efficacy and safety in the treatment of resistant-type proliferative lupus nephritis (PLN) and can be a suitably alternative treatment to extended-course of intravenous cyclophosphamide (ED-IVCY). Methods
Study to compare the efficacy and safety of EC-MPS vs an ED-IVCY in resistant-type PLN
32 biopsy-proven PLN, pts who failed to respond to an induction of IVCY were enrolled
Pts received 6 mo of EC-MPS treatment
Pts in the ED-IVCY group, collected from a database, received a repeated 6-mo course of monthly IVCY
Both groups received 0.5–1 mg/kg/day of prednisolone
Primary outcomes were partial or complete responses
A repeated kidney biopsy was performed to evaluate the histological response
.
Results
No serious AEs or patient deaths were observed during the study
Both groups had comparable baseline characteristics
At 6 mos, the EC-MPS group had a comparable response rate with the ED-IVCY group
There were less AE in the EC-MPS group
Repeated biopsies showed improvement in the EC-MPS group
